Показано 0 из 0
Дата |
---|
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.96
|
1.10
|
1.08
|
1.07
|
1.08
|
1.07
|
|
|
24.84
|
3.00
|
1.01
|
1.10
|
1.08
|
1.08
|
1.08
|
1.08
|
|
|
|
1.00
|
0.96
|
1.10
|
1.07
|
1.00
|
1.08
|
1.08
|
|
|
1 278.50
|
15.00
|
0.96
|
1.07
|
1.07
|
1.01
|
1.07
|
1.05
|
|
|
1 113.73
|
23.00
|
1.00
|
1.08
|
1.01
|
1.01
|
1.01
|
1.01
|
|
|
1.05
|
2.00
|
1.01
|
1.10
|
1.01
|
1.01
|
1.052
|
1.052
|
|
|
455.51
|
5.00
|
0.98
|
1.08
|
1.01
|
1.01
|
1.05
|
1.05
|
|
|
202.00
|
3.00
|
0.98
|
1.16
|
1.0499
|
1.0499
|
1.0499
|
1.0499
|
|
|
|
1.00
|
1.00
|
1.12
|
1.069
|
1.069
|
1.069
|
1.069
|
|
|
|
1.00
|
0.96
|
1.17
|
1.06
|
1.02
|
1.06
|
1.02
|
|
|
475.08
|
9.00
|
Estrella Immunopharma, Inc. operates as a preclinical-stage biopharmaceutical company. The Company focuses on developing CD19 and CD22-targeted T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella Immunopharma serves customers worldwide.